[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619437":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":13,"responsibleParty":34,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":7,"overallStatus":16,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","statin","Atorvastatin 40-80mg\u002Fday, Rosuvastatin 20mg\u002Fday",[14],{"facility":15,"status":16,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Lu Wang","RECRUITING","Shenyang","Liaoning","110840","China","CN",{"type":23,"coordinates":24},"Point",[25,26],123.43278,41.79222,{"lat":26,"lon":25},[29],{"name":30,"role":31,"phone":32,"phoneExt":7,"email":33},"Yu Cui","CONTACT","862428897491","cuiyu.spu@hotmail.com",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Hui-Sheng Chen","Director","100619437","effects-of-short-term-intensive-statin-therapy-on-lipid-levels-100619437",false,"NCT07344610","Effects of Short-term Intensive Statin Therapy on Lipid Levels","Effects of Short-term Intensive Statin Therapy on Lipid Levels in Patients With Ischemic Stroke or Large Artery Atherosclerosis: A Prospective Observational Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Diagnosis of ischemic stroke (within 14 days of onset) confirmed by cranial CT\u002FMRI; or imaging-confirmed intracranial\u002Fextracranial atherosclerotic stenosis (stenosis rate ≥ 50%);\n* Intensive statin therapy (e.g., atorvastatin 40-80 mg\u002Fday or rosuvastatin 20 mg\u002Fday) initiated within 24 hours of admission, with a planned continuous application for at least one week;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Use of statin therapy within 1 week prior to admission;\n* Receiving other lipid-lowering treatments;\n* Presence of other serious comorbidities (e.g., malignant tumors, end-stage heart failure) with an expected survival of \\\u003C1 year;\n* Pregnant or lactating women;\n* Participation in other drug clinical trials within 3 months;\n* Other conditions deemed unsuitable by the investigator.","ALL","18 Years",{"count":48,"type":49},800,"ESTIMATED","OBSERVATIONAL","Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques. However, patient response to intensive statin therapy varies significantly. This prospective study aims to analyze the short-term lipid-lowering effects and influencing factors of such therapy in ACI patients with stenosis, to guide personalized treatment and improve outcomes.",[53],"Ischemic Stroke","2026-01-07",{"date":56,"type":57},"2026-01-15","ACTUAL",{"date":59,"type":57},"2026-01-08",{"date":61,"type":49},"2026-12-30",{"name":5,"class":6},1]